BrainsWay (BWAY) announced that the U.S. National Institutes of Health, NIH, has awarded a new grant – totaling approximately $2.5 million over five years – to a research team led by Principal Investigator Dr. Claudia Padula and Co-Investigator Dr. Michelle Madore of Stanford University and the Palo Alto Veterans Institute for Research. The funding will support a clinical study evaluating the mechanism of action and potential efficacy of an accelerated Deep Transcranial Magnetic Stimulation protocol using BrainsWay’s device to treat Alcohol Use Disorder, AUD.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- Brainsway’s Strategic Investments and Growth Potential Drive Buy Rating with $17 Price Target
- Brainsway’s Deep TMS Study: A New Hope for Alcohol Use Disorder
- BrainsWay Expands U.S. Investments with New Mental Health Partnerships
- Brainsway enters two minority stake investments in mental health providers
- BrainsWay Announces Cashless Exercise of Warrant by Valor